Quilter 13F: Cuts Gilead Sciences (GILD) Stake by $638K

Quilter lowered its position in Gilead Sciences, Inc. GILD by 4,283 shares during the quarter, according to a Form 13F filing with the U.S. Securities and Exchange Commission on October 21, 2026. The filing showed the firm ending the period with 25,109 shares valued at approximately $3.74 million after a 14.6% reduction.

GILD Gilead Sciences, Inc.

$153.55 ▲ +28.55% year to date

1M 3M YTD

Daily close · Oct 21, 2026

What Changed in Quilter's Gilead Sciences Position

The reduction brought Quilter's holdings down from 29,392 shares in the previous period. The remaining stake reflects a smaller commitment to the drug maker as institutional managers adjust portfolios.

Other Institutional Activity in Gilead Sciences

Other large investors made notable adjustments to their positions in the biopharmaceutical company during recent reporting windows. CWA Asset Management Group grew its holdings by 15,240 shares, ending with 78,639 shares worth about $11.72 million following a 24.0% increase. ARS Wealth Advisors Group established a new holding with 1,458 shares valued at roughly $217,280. Caisse de Depot Et Placement Du Quebec expanded its investment significantly by 594,774 shares, bringing its total to 1,544,223 shares valued at about $195.10 million after a 62.6% jump. Massachusetts Financial Services lifted its position by 2,058,305 shares to reach 6,281,609 shares worth approximately $799.21 million, marking a 48.7% rise.

Gilead Sciences, Inc. Stock Down 1.7%

Gilead Sciences shares recently traded around $156.51 as of October 22, 2026, sitting above the stock's closing price of $153.57 on the filing date. The stock's recent level puts it roughly 6.3% above its 50-day moving average of $147.23 and about 13.3% higher than its 200-day moving average of $138.18. The share price is positioned 2.5% below its 52-week high of $160.51 and 37.3% above its 52-week low of $114.02.

Recent Earnings

Gilead Sciences reported trailing-twelve-month revenue of $30.46 billion alongside a trailing-twelve-month EPS of -$2.65. The company posted a negative return on equity of 20.7% and a net profit margin of -10.6% over the period, while revenue grew 10.2% year-over-year. The company's next earnings report is scheduled for October 29, 2026.

Dividend

The company distributes an annual dividend rate of $3.28 per share, translating to a dividend yield of 2.14%. Gilead allocates 43.5% of its earnings to dividend payments.

Insider Buying and Selling at Gilead Sciences, Inc.

Company insiders executed several planned stock sales under Rule 10b5-1 trading plans in recent months. Chief Comm & Corp Aff Officer Johanna Mercier sold 3,000 shares on June 15, 2026, at an average price of $123.92 for a total value of $371,771.70. Chief Financial Officer Andrew Dickinson sold 3,000 shares on the same date at $125.40 per share, totaling $376,200. Later, on October 15, 2026, Johanna Mercier sold another 3,000 shares at $156.22 per share for $468,660, while Andrew D Dickinson also sold 3,000 shares at $156.22 per share for $468,660.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the filing. Truist Securities maintained a Buy rating on October 7, 2026, lifting its target to $158.00 from $150.00. JP Morgan kept an Overweight rating on October 7, 2026, raising its target to $170.00 from $160.00. RBC Capital maintained a Sector Perform rating on October 8, 2026, moving its target to $126.00 from $123.00. Cantor Fitzgerald reiterated an Overweight rating on October 8, 2026, with a steady target of $155.00. B of A Securities maintained a Buy rating on October 20, 2026, pushing its target to $172.00 from $168.00. Analysts hold a consensus Buy rating on the stock with a mean price target of $160.15 across 26 analyst opinions.

About Gilead Sciences

Gilead Sciences, Inc. is a Foster City, California-based biopharmaceutical firm that discovers, develops, and markets medicines for severe medical conditions. Its product portfolio features antiviral treatments for HIV-1 infections, including therapies such as Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo, serving patients across the United States, Europe, and global markets.

Bottom Line

Investors will look toward Gilead Sciences' upcoming earnings release on October 29, 2026, for further clarity on financial performance and profit margins. Institutional adjustments and insider transaction patterns will continue to draw attention as market participants track the stock's positioning near its 52-week highs.